Trial · NCT01436084
SB1518 for Patients With Myelodysplastic Syndrome (MDS)
NCT01436084, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2016-06-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SB1518 for Patients With Myelodysplastic Syndrome (MDS). Trials, record NCT01436084. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01436084
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SB1518 for Patients With Myelodysplastic Syndrome (MDS)
- NCT number
- NCT01436084
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Leukemia
- Interventions
- SB1518
- First posted
- 2011-09-19
- Last updated
- 2016-07-13
- Results first posted
- 2016-06-15
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Overall Response | 28 days to one year | Overall response based on hematologic improvement defined by International Working Group (IWG) response criteria in myelodysplasia. Complete remission (CR): Bone marrow of 5% myeloblasts with normal maturation of all cell lines, noted persistent dysplasia; Partial Remission: CR criteria if abnormal before treatment except Bone marrow blasts decreased by 50% over pretreatment but still \> 5%; Marrow CR: Bone marrow 5% myeloblasts and decrease by 50% over pretreatment. Bone marrow aspirate pre-therapy (Day 0) and on Day 28 of first cycle then every 3 cycles. Responses must last at least 4 weeks. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Overall Response | 28 days to one year | Study was halted prior to completion of treatment and assessment for any participant(s). |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | SB1518 | 4 | |
| Overall Study | COMPLETED | SB1518 | 0 | |
| Overall Study | NOT COMPLETED | SB1518 | 4 |
Source ClinicalTrials.gov
Adverse events9
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | General disorders | SB1518 | 1 | 4 | 1 |
| other | Nausea | General disorders | SB1518 | 2 | 4 | 2 |
| other | Fatigue | General disorders | SB1518 | 2 | 4 | 2 |
| other | Gastrointestinal (GI) Other | Gastrointestinal disorders | SB1518 | 1 | 4 | 1 |
| other | Sweating | Skin and subcutaneous tissue disorders | SB1518 | 1 | 4 | 1 |
| other | Diarrhea | Gastrointestinal disorders | SB1518 | 2 | 4 | 2 |
| other | Pain Other | General disorders | SB1518 | 1 | 4 | 1 |
| other | Vomiting | General disorders | SB1518 | 1 | 4 | 1 |
| other | Heartburn | Gastrointestinal disorders | SB1518 | 1 | 4 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | SB1518 | ||
| Total, other adverse events | SB1518 | 2 | 4 |
| Total, serious adverse events | SB1518 | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01436084
GET https://conductscience.org/api/trials/v1/NCT01436084/registered